My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Systematic Stock Investing ...in less than a minute.
1. Is Sterling Biotech Ltd. a good quality company?
Data is not available for this company.
2. Is Sterling Biotech Ltd. undervalued or overvalued?
No data found
3. Is Sterling Biotech Ltd. a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Mar'16 | Mar'17 | Mar'18 | TTM | |||
| ROCE % ⓘ | 7% | 6.2% | 6.2% | 4.3% | -1% | -1.7% | -2.1% | -2.1% | -1.9% | -2% | - | ||
| Value Creation Index ⓘ | -0.5 | -0.6 | -0.6 | -0.7 | -1.1 | -1.1 | -1.2 | -1.2 | -1.1 | -1.1 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 1,178 | 1,438 | 1,617 | 1,662 | 835 | 718 | 667 | 419 | 368 | 352 | 408 | ||
| YoY Gr. Rt. % | - | 22.1% | 12.4% | 2.8% | -49.8% | -14% | -7.1% | -37.2% | -12.1% | -4.4% | - | ||
| Adj EPS ⓘ | 9.2 | 7.7 | 7.1 | 3.2 | -13 | -15 | -16.8 | -13.2 | -15.2 | -17.1 | -10.9 | ||
| YoY Gr. Rt. % | - | -16.8% | -7.8% | -54.3% | -503.4% | NA | NA | NA | NA | NA | - | ||
| BVPS (₹) ⓘ | 69.9 | 82.2 | 92 | 93 | 69.8 | 54.9 | 38.1 | 48.9 | 46.9 | 10.1 | -79.7 | ||
| Adj Net Profit ⓘ | 228 | 192 | 190 | 86.5 | -349 | -401 | -458 | -360 | -412 | -465 | -295 | ||
| Cash Flow from Ops. ⓘ | -98.7 | -1.3 | 348 | 370 | 811 | 172 | 256 | 53.6 | 1 | -32.8 | - | ||
| Debt/CF from Ops. ⓘ | -27.1 | -2339.6 | 10.8 | 11.5 | 4.5 | 22.6 | 18 | 98 | 7326.3 | -228.4 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | -12.6% | -15.9% | -19.2% | -4.4% | ||||||||
| Adj EPS ⓘ | -207.1% | NA | NA | NA | ||||||||
| BVPS ⓘ | -19.3 | -32 | -35.7 | -78.4 | ||||||||
| Share Price | - | - | - | - | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Mar'16 | Mar'17 | Mar'18 | TTM | ||
| Return on Equity % ⓘ | 15.1 | 10.1 | 8.4 | 3.5 | -16 | -24 | -22.8 | -21.4 | -28.1 | -59.9 | 31.2 | |
| Op. Profit Mgn % ⓘ | 42.5 | 35.2 | 43.1 | 38.4 | 17.7 | 13.2 | 12 | 12.3 | 3.4 | 4 | 9 | |
| Net Profit Mgn % ⓘ | 19.4 | 13.3 | 11.7 | 5.2 | -41.8 | -55.8 | -68.6 | -86 | -112 | -131.9 | -72.4 | |
| Debt to Equity ⓘ | 1.6 | 1.5 | 1.5 | 1.7 | 1.9 | 2.6 | 1.8 | 4 | 5.5 | 27.2 | - | |
| Working Cap Days ⓘ | 305 | 376 | 421 | 458 | 801 | 742 | 724 | 791 | 1,097 | 853 | 0 | |
| Cash Conv. Cycle ⓘ | 187 | 232 | 271 | 325 | 630 | 586 | 524 | 504 | 669 | 427 | 0 | |
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -10.9 | - |
| TTM Sales (₹ Cr.) | 408 | - |
| BVPS (₹.) ⓘ | -79.7 | - |
| Reserves (₹ Cr.) ⓘ | -2,197 | - |
| P/BV ⓘ | -0.01 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.77 / 0.85 |
| All Time Low / High (₹) | 0.67 / 262.45 |
| Market Cap (₹ Cr.) | 21 |
| Equity (₹ Cr.) | 27.2 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 29.8 |
| Pledged * | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 |
Working with and developing any opportunity into reality is a mindset at Sterling Group. Sterling Biotech Limited with its new thinking, new capabilities and sense of urgency aspires to “Earn trust, every moment” of its partners, collaborators, stake holders and customers.
The company is focusing to commercialize Active Pharmaceutical Ingredient (API) and make it available at competitive prices to its global customers.
The company’s capabilities include state of art research centre, advance pilot plant for scale up studies, modern facility of bioreactors and range of down streaming process equipments. All these are coupled with dedicated and qualified work force, well equipped quality control laboratory and quality assurance systems
The company strives to become leaders in API pharmaceutical area by developing state of the art facility for research and development, contract manufacturing of active pharmaceutical ingredients. It builds quality in every aspect of manufacturing with particular laid down emphasis based on current Good Manufacturing Practices.
The company is committed to scaling new heights and creating new dimensions in Fermentation based API and Synthetic API. This way it shall support aspiration to “Live better and Live longer”.
The company’s manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting CEP for the active pharmaceutical ingredient Epirubicin, Lovastatin
This adequately reflects Sterlings commitment towards quality. Efforts to attain such standards have also opened the key to gain foothold in the regulated and semi regulated markets throughout US and Europe
Business area of the company
The company is engaged in the manufacturing of Pharma Grade Gelatine & Di-Calcium Phosphate and other Pharma products. The Company has presence in both domestic and international markets.
Products
